Japanese encephalitis vaccine - Bavarian Nordic

Drug Profile

Japanese encephalitis vaccine - Bavarian Nordic

Alternative Names: MVA-BN JEV

Latest Information Update: 14 Jul 2008

Price : $50

At a glance

  • Originator Bavarian Nordic
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Encephalitis virus infections

Most Recent Events

  • 14 Jul 2008 Preclinical development is ongoing
  • 13 Jul 2007 European patent granted - 9077791
  • 11 Jul 2003 Preclinical trials in Encephalitis virus infections in European Union (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top